Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors

Environ Mol Mutagen. Apr-May 2007;48(3-4):159-65. doi: 10.1002/em.20296.
No abstract available

MeSH terms

  • Animals
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / pharmacology
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active / adverse effects
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / prevention & control*
  • Humans
  • Infant, Newborn
  • Lamivudine / adverse effects
  • Lamivudine / pharmacology
  • Lamivudine / therapeutic use
  • Maternal-Fetal Exchange
  • Pregnancy
  • Prenatal Exposure Delayed Effects
  • Reverse Transcriptase Inhibitors / adverse effects*
  • Reverse Transcriptase Inhibitors / pharmacology
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Risk Assessment
  • Zidovudine / adverse effects
  • Zidovudine / pharmacology
  • Zidovudine / therapeutic use

Substances

  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • Zidovudine